# Oral Testosterone for the Treatment of Hypogonadism in Males

> **NCT02222558** · PHASE2 · COMPLETED · sponsor: **TesoRx Pharma, LLC** · enrollment: 25 (actual)

## Conditions studied

- Hypogonadism

## Interventions

- **DRUG:** TSX-002

## Key facts

- **NCT ID:** NCT02222558
- **Lead sponsor:** TesoRx Pharma, LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-09
- **Primary completion:** 2015-04
- **Final completion:** 2015-05
- **Target enrollment:** 25 (ACTUAL)
- **Last updated:** 2016-05-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02222558

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02222558, "Oral Testosterone for the Treatment of Hypogonadism in Males". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT02222558. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*